Naringin ameliorates atherogenic dyslipidemia but not hyperglycemia in rats with type 1 diabetes

Journal of Cardiovascular Pharmacology

Volumn 59, Issue 2, 2012, Pages 133-141

  Xulu, Sphilile ^a   Oroma Owira, Peter Mark ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

atherosclerosis; diabetes; lipids; naringin

Indexed keywords

ACYL COENZYME A; AURANTIIN; CHOLESTEROL ACYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; ATHEROGENIC DYSLIPIDEMIA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NONHUMAN; POLYDIPSIA; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ATHEROSCLEROSIS; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DYSLIPIDEMIAS; FLAVANONES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; RATS; RATS, WISTAR; SIMVASTATIN; STREPTOZOCIN;

EID: 84857064728     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31823827a4     Document Type: Article

References (49)

1. Musunur K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids. 2010;45:907-914.
2. Ausin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-505.
3. National Cholesterol Education Program. Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Bethesda, MD: National Heart, Lung, and Blood Institute; 2002.
4. UK Prospective Diabetes Study 27: plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care. 1997;20: 1683-1687.
5. Syvanne M, Teskinen MR. Lipids and lipoproteins as coronary risk factors in noninsulin-dependent diabetes mellitus. Lancet. 1997;350 (suppl 1):S120-S123.
6. Winoccour PH, Durrington PN, Ishola M, et al. Influence of proteinuria on vascular disease, blood pressure, and lipoproteins in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed). 1987;294:1648-1651. (Pubitemid 17088016)
7. WHO. The cost of diabetes. Switzerland: WHO; 2003.
8. Jenkins AJ, Best JD, Klein RL, et al. Lipoproteins glycoxidation and diabetic angiopathy. Diabetes Metab Res Rev. 2004;20:349-368.
9. Knott HM, Brown BE, Davies MJ, et al. Glycation and glycoxidation of low-density lipoproteins by glucose and low-molecular mass aldehydes. Formation of modified and oxidized particles. Eur J Biochem. 2003;270: 3572-3582. (Pubitemid 37046738)
10. Haffner SM. Management of dyslipidemia in adults with type 2 diabetes. Diabetes Care. 1998;21:160-178. (Pubitemid 28030404)
11. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease. A statement for health care professionals from the American Heart Association. Circulation. 1999;100:1134-1146. (Pubitemid 29416243)
12. Rowland YK, Yeo WW. Lipid lowering in patients with diabetes mellitus: what coronary heart disease threshold should be used? Heart. 2002; 87:423-427. (Pubitemid 34454577)
13. Pyorala K, Pedersen TR, Kjeus J, Faegeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian simvastatin survival study (4S). Diabetes Care. 1997;20:614-620. (Pubitemid 27143424)
14. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation. 1998;98:2513-2519. (Pubitemid 29001188)
15. Heart Protection Study Collaborative Group. MRC/BHF heart protection collaborative study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo controlled trial. Lancet. 2002;360:7-22.
16. Arai H, Hiro K, Morimoto T, et al. JAPAN-ACS Investigators. More lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome. J Atheroscler Thromb. 2010;17:1096-1107.
17. Jung UJ, Lee MK, Park YB, et al. Effect of citrus flavonoids on lipid metabolism and glucose-regulating enzyme mRNA levels in type-2 diabetic mice. Int J Biochem Cell Biol. 2006;38:1134-1145.
18. Owira PMO, Ojewole JAO. The grapefruit: an old wine in a new glass? Metabolic and cardiovascular perspectives. Cardiovasc J Afr. 2010;21: 280-285.
19. Ribeiro IA, Ribeiro MHL. Naringing and naringenin determination and control in grapefruit juice by a validated HPLC method. Food Control. 2008;19:432-438. (Pubitemid 47571023)
20. Kim SY, Kim HJ, Jeon SM, et al. Naringin time-dependently lowers hepatic cholesterol biosynthesis and plasma cholesterol in rats fed high-fat and high-cholesterol diet. J Med Food. 2006;9:582-586.
21. Bok SH, Shin WY, Bae KH, et al. Effects of naringin and lovastatin on plasma and hepatic lipids in high-fat and high cholesterol fed rats. Nutr Res. 2000;20:1007-1015.
22. Gorinstein S, Leontowicz H, Leontowicz M, et al. Changes in plasma lipid and antioxidant activity in rats as a result of naringin and red grapefruit supplementation. J Agric Food Chem. 2005;53: 3223-3228. (Pubitemid 40525289)
23. Graf BA, Milbury PE, Blumberg JB. Flavonols, flavones, flavanones, and human health: epidemiological evidence. J Med Food. 2005;8: 281-290. (Pubitemid 41502409)
24. Jeon SM, Park YB, Choi MS. Antihypercholesterolemic property of naringin alters plasma and tissue lipids, cholesterol-regulating enzymes, fecal sterol and tissue morphology in rabbits. Clin Nutr. 2004;23: 1025-1034. (Pubitemid 39243016)
25. Jung UJ, Kim HJ, Lee JS, et al. Naringin supplementation lowers plasma lipids and enhances erythrocyte antioxidant enzyme activities in hypercholesterolemic subjects. Clin Nutr. 2003;22:561-568. (Pubitemid 37455724)
26. Ortiz-Andrade RR, Sánchez-Sagalo JC, Navarrete-Vázquez G,Webster SP, et al. Antidiabetic and toxicological evaluations of naringenin in normoglycemic and NIDDM rat models and its implication on extrapancreatic glucose regulation. Diabetes Obes Metab. 2008;10:1097-1104.
27. Babu PVA, Sabitha KE, Shyamaladevi CS. Green tea extract impedes dyslipidemia and development of cardiac dysfunction in streptozotocindiabetic rats. Clin Exp Pharmacol. 2006;33:1184-1189. (Pubitemid 44923906)
28. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanion. J Lipid Res. 1970;11:583-595.
29. Firedwald WT, Levy RI, Fredicksom DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
30. Rjadurai M, Prince PSM. Preventative effect of naringin on lipids, lipoproteins and metabolic enzymes in isoproterenol-induced myocardial infarction in Wistar rats. J Biochem Mol Toxicol. 2006;20: 191-197.
31. Folch J, Lees M, Sloane-Stanley GH. A simple method for isolation and purification of total lipids from animal tissues. J Biol Chem. 1957;226: 497-509.
32. Huchler MW, Oleson WH. Simplified spectrophotometric assay for microsomal 3-hydroxy-3-methylglutaryl CoA reductase by measurement of coenzyme A. J Lipid Res. 1973;14:625-631.
33. Shapiro DJ, Nordstrom JL, Mitschelen JJ, et al. Micro assay for 3-hydroxy-3-methylglutaryl CoA reductase in rat liver and in L-cell fibroblasts. Biochim Biophys Acta. 1974;370:369-377.
34. Erickson SK, Schrewsbery MA, Brooks C, et al. Rat liver acyl-coenzyme A:cholesterol acyltransferase: its regulation in vivo and some properties in vitro. J Lipid Res. 1980;21:930-941. (Pubitemid 11230315)
35. Gillies PJ, Rathgeb KA, Robinson CS. Regulation of acyl-coenzyme A: cholesterol acyltransferase in normal and atherosclerotic rabbit aortas: role of a cholesterol substrate pool. Exp Mol Pathol. 1986;44:320-339.
36. Choe SC, Kim HS, Jeong TS, et al. Naringin has an antiatherogenic effect with the inhibition of intracellular adhesion molecule-1 in hypercholesterolemic rabbits. J Cardiovasc Pharmacol. 2001;38:947-955.
37. Punithavathi VR, Anuthama R, Prince PS. Combined treatment with naringin and vitamin C ameliorates streptozotocin-induced diabetes in male Wistar rats. J Appl Toxicol. 2008;28:806-813.
38. Jung UJ, Lee MK, Jeong KS, et al. Hypoglycemic effects of hesperidin and naringin are partly mediated by hepatic glucose-regulating enzymes in C57BL/KsJ-db/db mice. J Nutr. 2004;134:2499-2503. (Pubitemid 39315245)
39. Aybar MJ, Riera ANS, Grau A, et al. Hypoglycemic effect of water extract of Smallanthus sonchifolius (Yacon) leaves in normal and diabetic rats. J Ethnopharmacol. 2001;74:125-132. (Pubitemid 32141094)
40. Kannapan S, Anuradha CV. Naringenin enhances insulin-stimulated tyrosine phosphorylation and improves cellular actions of insulin in a diabetic model of metabolic syndrome. Eur J Nutr. 2010;49:101-109.
41. Sharma AK, Bharti S, Ojha S, et al. Up-regulation of PPRg, heat shock protein-27 and -72 by naringin attenuates insulin resistance, b-cell dysfunction, hepatic steatosis and kidney damage. in a rat model of type 2 diabetes. Br J Nutr. 2011. doi:10.1017/s000711451100225X.
42. Amin D, Gustafson SK, Weinact JM, et al. RG 12561 (Dalvas-tatin): A novel synthetic inhibitor of HMG-CoA reductase and cholesterol lowering agent. Pharmacology. 1993;46:13-22. (Pubitemid 23027730)
43. Shand JH, West DW. The effects of simvastatin and cholestyramine, alone and in combination, on hepatic cholesterol metabolism in the male rat. Lipids. 1995;30:917-926.
44. Kim Y, Oh GT, Park YB, et al. Naringin alters cholesterol biosynthesis and antioxidant enzyme activities in LDL-receptor knockout mice under cholesterol fed condition. Life Sci. 2004;74:1621-1634. (Pubitemid 38114792)
45. Mulvihill EE, Allister EM, Sutherland BG, et al. Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL-receptor null mice with diet-induced insulin resistance. Diabetes. 2009;58:2198-2210.
46. Cho KW, Kim YO, Andrade JE, et al. Dietary naringenin increases hepatic peroxisome proliferators-activated receptor a protein expression and decreases plasma triglyceride and adiposity in rats. Eur J Nutr. 2011; 50:81-88.
47. Rizzo M, Pernice V, Frasheri A, et al. Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with metabolic syndrome. Clin Endocrinol. 2009;70:870-875.
48. Ueba T, Nomura S, Nishikawa T, et al. Circulating oxidized LDL, measured with FOH1a/DLH3 antibody, is associated with metabolic syndrome and the coronary heart disease risk score in healthy Japanese. Atherosclerosis. 2009;203:243-248.
49. Satoh N, Shimatsu A, Kotani K, et al. Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome. Hypertens Res. 2009;32: 934-935.